TScan Therapeutics (TCRX) Competitors

Esperion Therapeutics (NASDAQ:ESPR) and TScan Therapeutics (NASDAQ:TCRX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

Does the media refer more to ESPR or TCRX?

In the previous week, TScan Therapeutics had 11 more articles in the media than Esperion Therapeutics. MarketBeat recorded 14 mentions for TScan Therapeutics and 3 mentions for Esperion Therapeutics. TScan Therapeutics' average media sentiment score of 0.29 beat Esperion Therapeutics' score of 0.00 indicating that TScan Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Esperion Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TScan Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is ESPR or TCRX more profitable?

Esperion Therapeutics has a net margin of -35.84% compared to TScan Therapeutics' net margin of -1,964.88%. Esperion Therapeutics' return on equity of -0.91% beat TScan Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Esperion Therapeutics	-35.84%	-0.91%	-28.41%
TScan Therapeutics	-1,964.88%	-63.33%	-40.19%

Do analysts rate ESPR or TCRX?

Esperion Therapeutics currently has a consensus target price of $7.00, indicating a potential upside of 222.58%. TScan Therapeutics has a consensus target price of $7.80, indicating a potential upside of 317.11%. Given TScan Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe TScan Therapeutics is more favorable than Esperion Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Esperion Therapeutics	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
TScan Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more risk and volatility, ESPR or TCRX?

Esperion Therapeutics has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, TScan Therapeutics has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500.

Do institutionals and insiders believe in ESPR or TCRX?

47.4% of Esperion Therapeutics shares are owned by institutional investors. Comparatively, 82.8% of TScan Therapeutics shares are owned by institutional investors. 1.7% of Esperion Therapeutics shares are owned by insiders. Comparatively, 4.4% of TScan Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Which has higher valuation and earnings, ESPR or TCRX?

Esperion Therapeutics has higher revenue and earnings than TScan Therapeutics. Esperion Therapeutics is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Esperion Therapeutics	$332.31M	1.32	-$51.74M	-$0.49	-4.43
TScan Therapeutics	$6.96M	15.20	-$127.50M	-$1.09	-1.72

Summary

TScan Therapeutics beats Esperion Therapeutics on 10 of the 16 factors compared between the two stocks.